Interview 4 May 2017 This Belgian Startup is building the Next Generation of Diagnostic Tests DNAlytics changes the diagnosing game. The company builds in vitro diagnosis tests that save many years for patients! I met with Thibault, the founder, to know more about the company. Based in Louvain-La-Neuve, Belgium, DNAlytics develops revolutionary disease diagnostic processes that complement conventional methods. Their main product is RheumaKit, a test that analyzes biological and clinical […] May 4, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 3 May 2017 Immuno-oncology Pioneer Enters the Clinic with its RNA-based Therapy Rigontec has announced the start if its first-in-human Phase I/II study with its pioneering RNA-based candidate, RGT100, in solid tumors and lymphoma. Rigontec, based in Munich, is exploring RNA’s applications in immuno-oncology. Since the company was founded in 2014, it has raked in an impressive €30M in series A funding. Now, only 3 years later, the biotech is […] May 3, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
More News! 3 May 2017 German Pharma Investigates Genetics of Pain to Personalize Treatment At the height of the opioid epidemic, Grünenthal has partnered up with 23andMe to explore the genetic factors associated with pain. Though opioid abuse has not been as rampant in Europe as it has in the United States, German pharma Grünenthal, which focuses on pain, inflammation and gout, has staked out a position in the fight. Today, […] May 3, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 3 May 2017 E-GUIDE: This is how you bring a molecule to the clinic May 3, 2017 - 0 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 3 May 2017 New Immuno-oncology Biotech Gets a €20M Series A Funding Boost Imcheck Therapeutics from Marseille has just completed a €20M Series A funding round, backed by big investors like the Boehringer Ingelheim Venture Fund (BIVF). The French biotech Imcheck Therapeutics was founded in 2015 as a spin-off from the Paoli-Calmettes Cancer Institute (IPC) in Marseille and is developing next-generation immunomodulatory antibodies for the treatment of cancer and autoimmune diseases. […] May 3, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 3 May 2017 French Biotech gets a Second Opportunity to Fight Liver Fibrosis Genkyotex, a French biotech with an eye on NASH, has received FDA approval to initiate a Phase II trial in primary biliary cholangitis. Genkyotex’s lead candidate, GKT831, failed to prove its efficacy in a Phase II trial for diabetic nephropathy a couple of years ago. Now, the company is taking a second shot by targeting liver […] May 3, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 May 2017 Unexpected Side Effects: Are we Ready for the Rise of Immunotherapies? As immunotherapies are moving from large academic centers to clinics across the world, doctors are realizing that releasing the breaks of the immune system comes with serious risks – and that research on its adverse effects is lagging behind. This week, AstraZeneca’s anti-PD-L1 antibody durvalumab received FDA approval to treat patients with metastatic urothelial carcinoma, making […] May 3, 2017 - 4 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Interview 2 May 2017 Video Interview: Meet the Inventor of the Surgical Super-glue At our second meetup in Basel last week, Philip had the chance to talk to Maria Pereira, one of Forbes’ 30 under 30 and the scientific inventor of the technology behind Gecko Biomedical. Apart from telling us about Gecko’s progress and future plans, Maria talked about her time in Boston and why she ended up […] May 2, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 2 May 2017 Novartis Gains Access to Celyad’s allogenic CAR-T cell patents Belgian Celyad is giving Novartis access to its IP for the production of allogeneic CAR-T cells in a non-exclusive license agreement, worth up to €88M. Celyad is developing “off-the-shelf” therapies, based on engineering donor-derived allogeneic T cells. Despite a recent public dispute with its key rival Cellectis regarding the validity of Celyad’s US patents, Novartis has now entered a non-exclusive […] May 2, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 2 May 2017 French HIV Cure Reduces Viral Reservoirs for the First Time Ever Abivax has announced results from a Phase IIa trial that reveal the first proof in human of viral load reduction of hidden HIV reservoirs. Abivax is developing a functional HIV cure that, unlike current antiretroviral therapy (ART), could completely eliminate the virus and prevent it from coming back when the treatment is stopped. Results from a Phase IIa […] May 2, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 May 2017 Entrepreneurs, Academics & Entrepreneurial Academics succeed in Berlin With Berlin’s plethora of life science research and academia, opportunities abound for biotech entrepreneurs. Here’s how the city bridges the gap between science and business! So much research, so many opportunities for academics and entrepreneurs. Berlin boasts 35 large research institutions focused on life sciences, and around 130 hospitals — including Europe’s largest and most […] May 2, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 1 May 2017 This Founder is using Synbio to Revolutionize Genetic Medicine Oxford Genetics founder and CEO Ryan Cawood told me about his company’s improvements to DNA design for better biologicals. Last month at Synbiobeta, I caught up with Ryan Cawood, who created one of the most successful synthetic biology companies around, Oxford Genetics. “Our direction actually took off from this conference,” he told me. “We saw […] May 1, 2017 - 5 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email